Clinical trials: Parathyroid Dysfunction, open to volunteers
- Condition Parathyroid Dysfunction
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013…
- Trial name
- NCT06976177
- Testing
- MT1013
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
CKD Stage 3, CKD Stage 4
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D…
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Trial name
- NCT07494045
- Testing
- CTAP101
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- OPKO Health, Inc.
Cholecystitis, Cholecystitis, Chronic
Shortwave Infrared Surgical Imaging Device Study
The goal of this observational study is to perform an in-human assessment of an investigational shortwave infrared (SWIR) imaging device, aimed to enhance the visualization of critical anatomical structures during surgical…
- Conditions
- Cholecystitis, Cholecystitis, Chronic, Chronic Calculous Cholecystitis, Primary Hyperparathyroidism
- Trial name
- NCT07744425
- Testing
- Observational study of SWIR imaging device in surgery
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cision Vision, Inc.
Hypoparathyroidism
A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism
The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.
- Trial name
- NCT06988670
- Testing
- EXT608
- Where
- Argentina
- Volunteers
- 35 people
- Sponsor
- Extend Biosciences Inc.
Chronic Kidney Disease 5D, Secondary Hyperparathyroidism
A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.
The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis
- Trial name
- NCT06126016
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pregnant Individuals, Aneuploidy
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of…
- Conditions
- Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome
- Trial name
- ADVANCE (NCT07643896)
- Where
- 9 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- BillionToOne Inc.
Hypoparathyroidism
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed…
- Trial name
- NCT07264634
- Testing
- Palopegteriparatide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ascendis Pharma A/S
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active…
- Trial name
- NCT07122401
- Testing
- MT1013, Cinacalcet
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Secondary Hyperparathyroidism, Chronic Kidney Disease
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
- Trial name
- NCT03633708
- Testing
- Etelcalcetide, Standard of Care
- Where
- 43 sites in United States, Argentina and 8 more
- Volunteers
- 56 people
- Sponsor
- Amgen
Hypoparathyroidism, Chronic Hypoparathyroidism
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).
- Trial name
- RECLAIM-HP (NCT07805356)
- Testing
- Encaleret
- Where
- 5 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Approximately 56 participants who are 1 month old to 17 years old will be enrolled in this study. The total duration for this study will be 38 weeks (or up to 42 weeks when participants require a washout period due to prior…
- Trial name
- NCT07890584
- Testing
- PLS240, Standard of Care
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Pathalys Pharma
Hypoparathyroidism, Endocrine System Diseases
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day.
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Trial name
- PaTHway60 (NCT07081997)
- Testing
- Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ascendis Pharma Bone Diseases A/S
Hypoparathyroidism
A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
This trial will enroll adolescents between ages of ≥12 and <18 years with clinically diagnosed hypoparathyroidism . The purpose of the study is to see how well treatment with once-daily palopegteriparatide works and how safe it…
- Trial name
- NCT07706764
- Testing
- Palopegteriparatide
- Where
- 3 sites in France, Poland
- Volunteers
- 12 people
- Sponsor
- Ascendis Pharma A/S
Secondary Hyperparathyroidism
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in pediatric participants between ≥ 2 to < 18 years of age, with chronic…
- Trial name
- NCT03969329
- Testing
- Etelcalcetide
- Where
- 23 sites in Belgium, Czechia and 10 more
- Volunteers
- 24 people
- Sponsor
- Amgen
Hypoparathyroidism
A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).
- Trial name
- NCT07699471
- Testing
- Canvuparatide
- Where
- 22 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- MBX Biosciences
Hypoparathyroidism
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the…
- Trial name
- NCT07345494
- Testing
- Palopegteriparatide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ascendis Pharma A/S